“…Since the discovery of GluN2B-selective antagonists, numerous scaffolds of highly selective GluN2B NMDA receptor antagonists have been reported (reviewed by Layton et al, 2006;Mony et al, 2009;Koller and Urwyler, 2010;Ruppa et al, 2012). These include phenethanolamines such as ifenprodil (Williams, 1993), eliprodil (Carter et al, 1988), radiprodil (Michel et al, 2014;Auvin et al, 2020), traxoprodil (Chenard et al, 1995), Ro 25-6981 (Fischer et al, 1997), MK-0657 (Addy et al, 2009), plus additional scaffolds including propanolamines (Yuan et al, 2015), benzimidazoles (McCauley et al, 2004;Davies et al, 2012), cyclic benzamidines (Nguyen et al, 2007), amino cyclopentanes (Layton et al, 2011), piperidinyl pyrrolidinones (Marcin et al, 2018), and other compounds (Mosley et al, 2009;McIntyre et al, 2009;Brown et al, 2011;Buemi et al, 2014;Dey et al, 2018;Thum et al, 2018). Whereas crystallographic evaluation of ifenprodil at the GluN1/GluN2B heterodimer amino terminal domain (ATD) interface (Karakas et al, 2014) is the likely pose for many GluN2B-selective inhibitors, recent structural data revealed a unique region within the binding cavity that can be occupied by compounds with a more compact scaffold (Kemp and Tasker, 2009;Stroebel et al, 2016).…”